In hopes of changing survival rates, the Ohio State Wexner Medical Center researcher Zobeida Cruz-Monserrate, PhD, has been awarded multiple grants to understand why pancreatic cancer cells express specific proteins, explore whether those proteins could serve as early detection biomarkers and discover if blocking them could serve as effective therapy. Read more . . .
To date, no biomarker has been identified that is specific enough to detect pancreatic cancer at an early stage and no reliable treatments.[/subhed]